We are a high-tech enterprise engaged in theresearch, development, manufacture, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines, or TCM, in the People’s Republic of China (“PRC” or “China”). We have three “Good Manufacturing Practice” or GMP certified production facilities - Ah City Natural and Biopharmaceutical plant, Dongfanghong pharmaceutical plant and Qingyang natural extraction plant -capable of producing 18 dosage forms and over 200 different products. Our products include but are not limited to (i) botanical anti-depression and nerve-regulation products, (ii) biopharmaceutical products, and (iii) botanical antibiotic and traditional over-the-counter (“OTC”) Chinese medicines. Botanical anti-depression and nerve-regulation products account for approximately 70% of our revenues and we intend to strengthen our development in this area. We have entered into sales agency agreements with our sales agents through them our products are sold to over 3,000 distributors and over 70 sales centers across 24 provinces in China.
Company profile
Ticker
FBDS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ANZA CAPITAL INC, China Botanic Pharmaceutical, SUARRO COMMUNICATIONS INC, COMTECH CONSOLIDATION GROUP INC, E NET CORP, E NET CORP/NV, E NET FINANCIAL CORP, E-NET COM CORP, E-NET FINANCIAL COM CORP, RENHUANG PHARMACEUTICALS INC, SOLUTIONS INC
SEC CIK
Corporate docs
IRS number
841273503
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
18 Mar 24
10-K
2023 FY
Annual report
5 Feb 24
NT 10-K
Notice of late annual filing
29 Jan 24
8-K
Resolution of the Shareholders of
11 Jan 24
10-Q
2023 Q3
Quarterly report
5 Sep 23
10-Q
2023 Q2
Quarterly report
12 Jun 23
10-Q
2023 Q1
Quarterly report
9 Mar 23
8-K
Entry into a Material Definitive Agreement
2 Mar 23
10-K
2022 FY
Annual report
27 Jan 23
8-K
Entry into a Material Definitive Agreement
27 Jan 23
Latest ownership filings
Financial summary
Quarter (USD) | Jul 23 | Apr 23 | Jan 23 | Oct 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 22 | Oct 21 | Oct 20 | Oct 13 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.03 k | 23.03 k | 23.03 k | 23.03 k | 23.03 k | 23.03 k |
Cash burn (monthly) | (no burn) | 2.32 k | 38.61 k | 33.36 k | 12.79 k | 10.48 k |
Cash used (since last report) | n/a | 18.41 k | 306.79 k | 265.05 k | 101.66 k | 83.23 k |
Cash remaining | n/a | 4.62 k | -283.76 k | -242.02 k | -78.63 k | -60.20 k |
Runway (months of cash) | n/a | 2.0 | -7.3 | -7.3 | -6.1 | -5.7 |